Cantitate/Preț
Produs
Total produse
Vezi coșul
Chronic Lymphocytic Leukemia de Michael Hallek

Chronic Lymphocytic Leukemia: Hematologic Malignancies

Editat de Michael Hallek, Barbara Eichhorst, Daniel Catovsky
en Limba Engleză Hardback – 6 mai 2019

Adresată medicilor hematologi și oncologilor aflați în diverse stadii de practică clinică, lucrarea Chronic Lymphocytic Leukemia sintetizează cunoștințele actuale despre cea mai frecventă formă de leucemie la adulți. Remarcăm o abordare integrată care pornește de la bazele fiziopatologice și avansează spre complexitatea diagnosticului și a managementului terapeutic modern. Structura volumului, editat de Michael Hallek, Barbara Eichhorst și Daniel Catovsky, reflectă o progresie logică: de la stabilirea markerilor de prognostic până la protocoalele de urmărire și gestionarea complicațiilor.

Credem că elementul distinctiv al acestei ediții este analiza detaliată a modului în care înțelegerea mecanismelor moleculare a transformat radical paradigma terapeutică. Autorii explică riguros modul în care alegerea tratamentului depinde acum nu doar de stadiul bolii și vârsta pacientului, ci și de aberațiile genetice specifice. Această abordare completează volumul Advances in Chronic Lymphocytic Leukemia de Sami Malek prin accentul pus pe ghidarea practică în utilizarea procedurilor de diagnostic și a strategiilor de primă linie în caz de recădere. În timp ce alte lucrări se pot concentra pe biologia fundamentală, volumul de față oferă o perspectivă clinică aplicată, incluzând secțiuni valoroase despre entități rare precum leucemia prolimfocitară cu celule T. Ritmul expunerii este unul dens, specific literaturii medicale de înalt nivel, facilitând o actualizare rapidă a protocoalelor de intervenție, inclusiv pentru proceduri complexe precum transplantul alogen de celule stem.

Citește tot Restrânge

Din seria Hematologic Malignancies

  • 5% Acute Leukemias
    Preț: 78635 lei
  • 5% Infection Management in Hematology
    Preț: 99479 lei
  • 5% Rare Lymphomas
    Preț: 70970 lei
  • 5% Myeloproliferative Disorders
    Preț: 107531 lei
  • 5% Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders
    Preț: 138647 lei
  • 5% Hematologic Malignancies: Acute Leukemias
    Preț: 151956 lei
  • 5% Multiple Myeloma and Other Plasma Cell Neoplasms
    Preț: 106037 lei
  • 5% Myelodysplastic Syndromes
    Preț: 77990 lei
  • 5% Myeloproliferative Neoplasms
    Preț: 75383 lei
  • 5% Myelodysplastic Syndromes: Diagnosis - Prognosis - Therapy
    Preț: 71520 lei
  • 5% Aggressive Lymphomas
    Preț: 93302 lei
  • 5% Chronic Myeloid Leukemia
    Preț: 58505 lei
  • 5% Hodgkin Lymphoma
    Preț: 89053 lei
  • 5% Indolent Lymphomas
    Preț: 77862 lei
  • 5% Acute Myeloid Leukemia
    Preț: 82314 lei

Preț: 67302 lei

Preț vechi: 70844 lei
-5%

Puncte Express: 1010

Carte tipărită la comandă

Livrare economică 13-18 iulie

Livrare prin curier în România Termenul estimat este afișat lângă disponibilitate.
Transport gratuit pentru acest produs Plată online sau ramburs, în funcție de opțiunile comenzii.
Retur gratuit în 14 zile Comandă securizată și suport în română.
 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă

Specificații

ISBN-13: 9783030113919
ISBN-10: 3030113914
Pagini: 188
Ilustrații: VI, 179 p. 23 illus., 19 illus. in color.
Dimensiuni: 183 x 260 x 16 mm
Greutate: 0.6 kg
Ediția:1st ed. 2019
Editura: Springer
Colecția Hematologic Malignancies
Seria Hematologic Malignancies

Locul publicării:Cham, Switzerland

De ce să citești această carte

Recomandăm această lucrare ca o resursă esențială pentru clinicienii care doresc să stăpânească noile protocoale de tratament personalizat în LLC. Cititorul câștigă o înțelegere profundă a markerilor de prognostic și a managementului complicațiilor, beneficiind de expertiza unor lideri de opinie internaționali. Este un instrument indispensabil pentru tranziția de la terapiile convenționale la cele țintite genetic.

Despre autor

Michael Hallek, Barbara Eichhorst și Daniel Catovsky sunt figuri proeminente în hematologia mondială, asociați cu grupuri de studiu de prestigiu care au definit standardele de îngrijire în leucemia limfocitară cronică. Michael Hallek este recunoscut pentru contribuțiile sale majore în cercetarea clinică și dezvoltarea strategiilor terapeutice moderne, în timp ce Barbara Eichhorst și Daniel Catovsky aduc decenii de experiență în diagnosticarea și tratarea malignităților hematologice. Expertiza lor combinată asigură rigoarea științifică a seriei Hematologic Malignancies de la Springer.

Descriere scurtă

This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapyof T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed.
 

Cuprins

Pathophysiolgoy.- Diagnostics.- Clinical Presentation.- Prognostic Markers.- Treatment.- Follow-up and Complications.- Related Entities.

Notă biografică

Michael Hallek, MD, received his medical degree from the University of Munich, Germany, in 1985. From 1985 to 1990, he trained in pharmacology and internal medicine at that university and at the Technical University of Munich. He then spent two years as a research associate at the Dana Farber Cancer Institute at Harvard Medical School, Boston, USA, before returning to the University of Munich, where he continued his training in internal medicine and in hematology and oncology. From 1994 to 2005, he was head of the Gene Therapy Program at the Gene Center of the University of Munich and at the National Center for Research on Environment and Health (GSF), Munich. In 1994, he founded the German CLL Study Group (DCLLSG) and has remained its chairman until today. Since 2003, Dr. Hallek has been Professor of Medicine, Director, and Chair of the Department I of Internal Medicine at the University of Cologne. Since 2007, he has also been chairman of the Center for Integrated Oncology (CIO), the joint comprehensive cancer center of the Universities of Cologne and Bonn. In 2011, he became a member of the National Academy of Sciences (Leopoldina). Besides numerous awards, he has received the honour of the Ham-Wasserman Lecture during the American Society of Hematology in 2018. Since 2018, he has been chairman of the scientific committee of the European School of Haematology, Paris.
Barbara Eichhorst, MD, PhD, graduated from the Medical School of the University of Munich in 1997. She did her doctoral thesis in the field of hematology, evaluating signaling transduction pathways in Hodgkin cells. Dr. Eichhorst completed an internship at the Department III for Internal Medicine at Klinikum Großhadern of the University of Munich before becoming a consultant for internal medicine. She has worked at the University Hospital of Cologne since February 2005 and was appointed a consultant in hematology and internal oncology there in April 2006. She becameassistant professor at the University of Cologne in December 2012 and is a consultant in Department I for Internal Medicine at the University Hospital of Cologne. Shortly after the foundation of the German CLL Study Group (GCLLSG) she became a member of its leading group, acting as principal investigator in several phase II and III trials evaluating treatment optimization in CLL. Since 2005 she has been secretary of the GCLLSG. Dr. Eichhorst has published a number of papers on the topic of treatment of CLL within clinical trials, and she is a globally recognized specialist in the field of CLL. 
Daniel Catovsky, MD, DSc(Med), FRCPath, FMedSci, is Emeritus Professor and Fellow in the Division of Molecular Pathology at The Institute of Cancer Research, London, UK. Dr. Catovsky obtained his medical degree in Buenos Aires in 1961 and from 1967 worked under David Galton in the MRC Leukaemia Unit at the Hammersmith Hospital and Royal Postgraduate Medical School, where he was awarded a personal chair in hemato-oncology. In 1988 he became Head of Haematology at the Royal Marsden Hospital and The Institute of Cancer Research. A world authority on chronic adult leukemias, he has held visiting professorships in many countries, served on the editorial board of ten national and international journals, and published over 850 book chapters and papers in peer-reviewed journals. One of the key people who brought CLL, the most common adult leukemia, to the attention of the research community, he has been coordinator of the UK CLL Trials 1, 2, 3, 4, and 5. His work in hairy cell leukemia has helped to transform the prognosis for patients with this disease. He has served on a variety of review and advisory boards and has been President of the British Society of Haematology (1996–7) and of the European Research Initiative on CLL (ERIC) (2006–2009). He has received the BSH Medal for contributions to British hematology (2000) and the Binet-Rai medal for outstanding contributions to CLL research (2005). 

Caracteristici

Summarizes current knowledge on all aspects of CLL Describes the role of different diagnostic procedures Examines the changing treatment paradigm in CLL and the emergence of new therapeutic targets Equips readers to make the most appropriate treatment choice in individual patients